Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late?

Table 2 Recurrence characteristics

	mTOR inhibitor (n = 79)	No mTOR inhibitor (n = 64)	P value
Date of recurrence	7/2013	3/2008	< 0.001
Age at recurrence (years)	58 (52-64)	55 (46-61)	0.06
Time from transplant (mo)	12 (6-24)	12 (5-25)	0.73
Number of tumours	2 (1-5)	5 (1-9)	0.02
Size of largest tumour (cm)	2.0 (1.1-3.2)	2.1 (1.1-3.9)	0.74
Number of organs involved	1 (1-1)	1 (1-2)	0.50
Site of recurrence
Liver	34 (43%)	28 (44%)	0.93
Lung	36 (46%)	35 (55%)	0.33
Bone	17 (22%)	6 (9%)	0.049
Peritoneum	4 (5%)	8 (13%)	0.11
Adrenal	5 (6%)	6 (9%)	0.50
Lymph node	6 (8%)	4 (6%)	0.75
AFP upon recurrence (ng/mL)	14 (4-139)	32 (6-855)	0.19
Immunosuppression
Calcineurin Inhibitor	49 (62%)	62 (97%)	< 0.001
Tacrolimus level	3.0 (0-4.9)	5.2 (3.7-6.1)	0.03
Treatment
Surgery	22 (28%)	11 (17%)	0.13
RFA	7 (9%)	6 (9%)	0.89
TACE	19 (24%)	10 (16%)	0.23
Radiotherapy	31 (39%)	14 (22%)	0.03
Targeted therapy	47 (59%)	15 (23%)	< 0.001
Immunotherapy	2 (3%)	0 (0%)	0.18
Supportive	3 (4%)	23 (36%)	< 0.001

AFP: Alpha-fetoprotein; RFA: Radiofrequency ablation; TACE: Trans-arterial chemoembolization; mTOR: Mammalian target of rapamycin.